comparemela.com

Latest Breaking News On - Company exo - Page 1 : comparemela.com

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

TORONTO and HAIFA, Israel, Oct. 30, 2023 (GLOBE NEWSWIRE) NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”).

United statesEva reuterLior shaltielCompany annual information formIsrael institute of technologyCompany exotherapyThesis capital incNurexone biologic incTel aviv universityRegulation services providerCompany exoCompany or nurexoneNurexone biologic ltdDrug administrationVenture exchangeExone biologic

NurExone Biologic Receives FDA Orphan-Drug Designation,

NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment .

United statesEva reuterLior shaltielDrug administrationThesis capital incNurexone biologic ltdTel aviv universityIsrael institute of technologyCompany exoCompany exotherapyNurexone biologic incCompany or nurexoneExone biologicOrphan drug designationNurexone biologicIsrael institute

NurExone Moves Forward Towards Human Clinical Trials,

The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be.

Lior shaltielCompany exoDrug administrationCompany or nurexoneIsrael institute of technologyCompany exotherapyTel aviv universityNurexone biologic incExone biologicPre investigational new drugIsrael instituteExecutive officerTsx venture exchange nrxNurexone biologic incReind meetingClinical trials

vimarsana © 2020. All Rights Reserved.